Targacept Archives - Page 2 of 2 - World Asthma Foundation

Targacept reports mixed data from two trials – Reuters

Targacept reports mixed data from two trials
Reuters
* Says asthma trial meets main goals * Says diabetes trial did not meet main goal * Targacept drops development of drug for diabetes March 27 (Reuters) – Targacept said an experimental drug proved effective in a mid-stage asthma trial, but failed to …
Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of …MarketWatch (press release)
Targacept Dropping Development Of Diabetes Drug; Shares FallWall Street Journal
Targacept Reports Top-Line Results From 2 Exploratory Phase 2 Studies Of TC-6987RTT News

all 14 news articles »

Targacept Reports Top-Line Results From 2 Exploratory Phase 2 Studies Of TC-6987
RTT News
(RTTNews) – Targacept Inc. (TRGT: News ) announced top-line results from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in the US, one in asthma and one in type 2 diabetes. In the asthma study, oral TC-6987 met …
Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of …MarketWatch (press release)

all 6 news articles »

Targacept Begins Phase 2 Studies of TC-6987 in Asthma and Type 2 Diabetes
Trading Markets (press release)
TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes …

and more »

Targacept initiates two anti-inflammatory drug studies
Pharmaceutical Business Review
Targacept has initiated two separate Phase II studies of its product candidate TC-6987 in disorders characterised by inflammation, in asthma and Type II …
Targacept to begin Phase 2 trials of drug that could treat asthma, diabetesWinston-Salem Journal
Targacept starts new trial for diabetes drugBizjournals.com
TARGACEPT : Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and …4-traders (press release)

all 18 news articles »

Targacept to begin Phase 2 trials of drug that could treat asthma, diabetes
Winston-Salem Journal
Type 2 diabetes affects 198 million worldwide, and asthma affects about 65 million in just the world's seven major pharmaceutical markets — France, Germany …
Targacept starts new trial for diabetes drugBizjournals.com
TARGACEPT : Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and …4-traders (press release)

all 17 news articles »

Targacept Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and …
EON: Enhanced Online News (press release)
TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes …
Targacept to begin phase 2 trials for its anti-inflammatory drug compoundWinston-Salem Journal
Targacept starts new trial for diabetes drugBizjournals.com

all 13 news articles »

Targacept to begin phase 2 trials for its anti-inflammatory drug compound
Winston-Salem Journal
… said that the studies involve its drug compound TC-6987 for disorders related to inflammation – in this instance asthma and Type 2 diabetes. …
Targacept starts new trial for diabetes drugBizjournals.com
TARGACEPT : Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and …4-traders (press release)

all 13 news articles »

Targacept starts new trial for diabetes drug
Bizjournals.com
Targacept will take a drug it hopes will become a treatment for asthma and Type 2 diabetes into a Phase 2 clinical trial, the company has announced. …
Targacept to begin phase 2 trials for its anti-inflammatory drug compoundWinston-Salem Journal
TARGACEPT : Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and …4-traders (press release)

all 12 news articles »

TARGACEPT : Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and …
4-traders (press release)
TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes …

and more »

Targacept Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and …
Genetic Engineering News (press release)
TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes …

and more »